Literature DB >> 6332189

Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflect.

M Danhof, M Hisaoka, G Levy.   

Abstract

The purpose of this investigation was to determine if renal dysfunction is associated with an alteration in the concentration-pharmacologic activity relationship of phenobarbital (PB). Adult female rats (congruent to 200 g) were pretreated with uranyl nitate or subjected to bilateral ureteral ligation to produce renal dysfunction. Saline-injected and sham-operated rats, respectively, served as controls. PB (0.824 mg/min) was infused i.v. until the animals lost their righting reflex (LRR). Renal dysfunction reduced the total dose of PB required to produce LRR, the concentrations of total and free (unbound) PB in serum and the concentrations of PB in brain and cerebrospinal fluid at onset of LRR. Results were quantitatively similar in both experimental models of impaired renal function. Concomitant infusion of p-hydroxyphenobarbital (the major metabolite of PB) and PB in rats with uranyl nitrate-induced renal dysfunction had no effect on the PB concentrations at onset of LRR. When PB was infused at different rates (either 0.412, 0.824, 2.04 or 4.12 mg/min), rats with renal dysfunction had increasing concentrations of PB at onset of LRR with increasing infusion rate, not only in serum and brain but also (unlike normal rats) in cerebrospinal fluid. Thus, renal dysfunction is associated with increased sensitivity to PB and with a change in the kinetic relationship between PB in cerebrospinal fluid and in the biophase.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332189

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions.

Authors:  J W Mandema; P Veng-Pedersen; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-12

2.  Morphine intoxication in renal failure: the role of morphine-6-glucuronide.

Authors:  H L Gordon
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-27

3.  Gender differences in the pharmacodynamics of barbiturates in rats.

Authors:  A Hoffman; G Levy
Journal:  Pharm Res       Date:  1989-11       Impact factor: 4.200

4.  Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure.

Authors:  S H Kim; H J Shim; W B Kim; M G Lee
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing.

Authors:  J van Harten; J Burggraaf; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 6.  Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability.

Authors:  G Levy
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

Review 7.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

8.  Pharmacodynamics of zoxazolamine and chlorzoxazone in rats.

Authors:  M Yasuhara; G Levy
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

9.  Altered pharmacokinetics and dynamics of apomorphine in the malnourished rat: modeling of the composed relationship between concentration and heart-rate response.

Authors:  E Bredberg; L K Paalzow
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

10.  Kinetics of drug action in disease states. XXXIX. Effect of orally administered activated charcoal on the hypnotic activity of phenobarbital and the neurotoxicity of theophylline administered intravenously to rats with renal failure.

Authors:  A Hoffman; G Levy
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.